Stereotaxis expects recurring revenue to reach approximately $8 million in the fourth quarter of 2026, driven by adoption of its proprietary MAGiC catheters, though sales remain supply constrained with catheters on backlog. CEO David Fischel said recurring revenue surpassed $6 million in the second quarter, a multi-year high, and guided for an approximate $1 million incremental step up in catheter revenue in each of the next couple quarters. System revenue is expected to strengthen to about $3 million in each of the third and fourth quarters, supported by multiple Synchrony shipments and one system revenue recognition per quarter. The company reported second-quarter total revenue of $7.7 million, with system revenue of $1.5 million and recurring revenue of $6.2 million, while gross margin was 58% and net loss was $4.5 million. Stereotaxis is internally modeling to reach cash flow profitability in the first half of 2027, relying on catheter adoption and modest capital assumptions.
Stereotaxis IncRecurring revenue growth driven by MAGiC catheter adoption, though supply constrained.
